In the last 12 months, insiders at Replimune Group, Inc. ($REPL) filed 69 transactions with the SEC: 0 open-market purchases totaling $0 and 23 sales totaling $2,013,562. Net insider sentiment: net selling.
Replimune Group, Inc. operates in the Biological products, (no disgnostic substances) industry (Life sciences sector).
Most Active Insiders
- Patel Sushil (Chief Executive Officer) — 9 transactions totaling $568,501
- Xynos Konstantinos (Chief Medical Officer) — 10 transactions totaling $368,464
- Astley-Sparke Philip (Director) — 2 transactions totaling $260,169
- Astley-Sparke Philip (Executive Chairman) — 2 transactions totaling $245,394
- Hill Emily Luisa (Chief Financial Officer) — 8 transactions totaling $160,553
View all SEC Filings for Replimune Group, Inc. (REPL).
Set Up your own filters →Recent Insider Transactions
| Transaction Date | Insider Name | Title | Transaction Type | Security | Shares | Price | Shares Owned Following | Total Shares Outstanding | % of Owned | % of Outstanding |
|---|---|---|---|---|---|---|---|---|---|---|
| Feb. 18, 2026 | Astley-Sparke Philip | Director | G | Common Stock | 25000 | $0.00 | 1,380,071.0000 | 92,187,581 | 1.78% | 0.03% |
| Dec. 19, 2025 | Schwendenman Andrew | Chief Accounting Officer | A | Common Stock | 10000 | $0.00 | 78,284.0000 | 91,915,769 | 14.64% | 0.01% |
| Dec. 19, 2025 | Patel Sushil | Chief Executive Officer | A | Common Stock | 200000 | $0.00 | 533,576.0000 | 91,915,769 | 59.96% | 0.22% |
| Dec. 19, 2025 | Xynos Konstantinos | Chief Medical Officer | A | Common Stock | 60000 | $0.00 | 199,685.0000 | 91,915,769 | 42.95% | 0.07% |
| Dec. 19, 2025 | Hill Emily Luisa | Chief Financial Officer | A | Common Stock | 60000 | $0.00 | 194,368.0000 | 91,915,769 | 44.65% | 0.07% |
| Dec. 19, 2025 | Sarchi Christopher | Chief Commercial Officer | A | Common Stock | 35000 | $0.00 | 158,088.0000 | 91,915,769 | 28.43% | 0.04% |
| Dec. 9, 2025 | Dhingra Kapil | Director | S | Common Stock | 3169 | $10.40 | 0.0000 | 91,915,769 | 100.00% | 0.00% |
| Dec. 9, 2025 | Dhingra Kapil | Director | M | Stock Option (right to buy) | 3169 | $0.00 | 0.0000 | 91,915,769 | 100.00% | 0.00% |
| Dec. 9, 2025 | Dhingra Kapil | Director | M | Common Stock | 3169 | $1.75 | 3,169.0000 | 91,915,769 | 9999.99% | 0.00% |
| Dec. 2, 2025 | Patel Sushil | Chief Executive Officer | S | Common Stock | 10000 | $11.13 | 333,576.0000 | 91,915,769 | 2.91% | 0.01% |
| Nov. 17, 2025 | Xynos Konstantinos | Chief Medical Officer | S | Common Stock | 7248 | $9.10 | 139,685.0000 | 91,915,769 | 4.93% | 0.01% |
| Nov. 17, 2025 | Sarchi Christopher | Chief Commercial Officer | S | Common Stock | 5208 | $9.10 | 123,088.0000 | 91,915,769 | 4.06% | 0.01% |
| Aug. 15, 2025 | Hill Emily Luisa | Chief Financial Officer | S | Common Stock | 9154 | $5.37 | 134,368.0000 | 80,564,147 | 6.38% | 0.01% |
| May 20, 2025 | Hill Emily Luisa | Chief Financial Officer | S | Common Stock | 2535 | $8.05 | 143,522.0000 | 80,564,147 | 1.74% | 0.00% |
| May 20, 2025 | Astley-Sparke Philip | Director | S | Common Stock | 32279 | $8.06 | 1,405,071.0000 | 80,564,147 | 2.25% | 0.04% |
| May 20, 2025 | Xynos Konstantinos | Chief Medical Officer | S | Common Stock | 7952 | $8.06 | 146,933.0000 | 80,564,147 | 5.13% | 0.01% |
| May 20, 2025 | Schwendenman Andrew | Chief Accounting Officer | S | Common Stock | 3287 | $8.05 | 68,284.0000 | 80,564,147 | 4.59% | 0.00% |
| May 20, 2025 | Patel Sushil | Chief Executive Officer | S | Common Stock | 25105 | $8.06 | 343,576.0000 | 80,564,147 | 6.81% | 0.03% |
| May 20, 2025 | Sarchi Christopher | Chief Commercial Officer | S | Common Stock | 3749 | $8.05 | 128,296.0000 | 80,564,147 | 2.84% | 0.00% |
| April 1, 2025 | Hill Emily Luisa | Chief Financial Officer | A | Common Stock | 45000 | $0.00 | 146,057.0000 | 80,564,147 | 44.53% | 0.06% |
| April 1, 2025 | Peeples-Dyer Veleka | Director | A | Stock Option (right to buy) | 32000 | $0.00 | 32,000.0000 | 80,564,147 | 9999.99% | 0.04% |
| April 1, 2025 | Patel Sushil | Chief Executive Officer | A | Common Stock | 166667 | $0.00 | 368,681.0000 | 80,564,147 | 82.50% | 0.21% |
| April 1, 2025 | Patel Sushil | Chief Executive Officer | A | Employee Stock Option (right to buy) | 250000 | $0.00 | 250,000.0000 | 80,564,147 | 9999.99% | 0.31% |
| April 1, 2025 | Pucci Paolo | Director | A | Stock Option (right to buy) | 32000 | $0.00 | 32,000.0000 | 80,564,147 | 9999.99% | 0.04% |
| April 1, 2025 | Balachandran Madhavan | Director | A | Stock Option (right to buy) | 32000 | $0.00 | 32,000.0000 | 80,564,147 | 9999.99% | 0.04% |
| April 1, 2025 | Xynos Konstantinos | Chief Medical Officer | A | Common Stock | 45000 | $0.00 | 154,885.0000 | 80,564,147 | 40.95% | 0.06% |
| April 1, 2025 | Xynos Konstantinos | Chief Medical Officer | A | Employee Stock Option (right to buy) | 67500 | $0.00 | 67,500.0000 | 80,564,147 | 9999.99% | 0.08% |
| April 1, 2025 | Dhingra Kapil | Director | A | Stock Option (right to buy) | 32000 | $0.00 | 32,000.0000 | 80,564,147 | 9999.99% | 0.04% |
| April 1, 2025 | SLATTERY JOSEPH P | Director | A | Stock Option (right to buy) | 32000 | $0.00 | 32,000.0000 | 80,564,147 | 9999.99% | 0.04% |
| April 1, 2025 | Hill Emily Luisa | Chief Financial Officer | A | Employee Stock Option (right to buy) | 67500 | $0.00 | 67,500.0000 | 80,564,147 | 9999.99% | 0.08% |
| April 1, 2025 | Weinand Dieter | Director | A | Stock Option (right to buy) | 32000 | $0.00 | 32,000.0000 | 80,564,147 | 9999.99% | 0.04% |
| April 1, 2025 | Sarchi Christopher | Chief Commercial Officer | A | Common Stock | 45000 | $0.00 | 132,045.0000 | 80,564,147 | 51.70% | 0.06% |
| April 1, 2025 | Sarchi Christopher | Chief Commercial Officer | A | Employee Stock Option (right to buy) | 67500 | $0.00 | 67,500.0000 | 80,564,147 | 9999.99% | 0.08% |
| April 1, 2025 | Oliger Christy J. | Director | A | Stock Option (right to buy) | 32000 | $0.00 | 32,000.0000 | 80,564,147 | 9999.99% | 0.04% |
| April 1, 2025 | Schwendenman Andrew | Chief Accounting Officer | A | Common Stock | 33333 | $0.00 | 71,571.0000 | 80,564,147 | 31.77% | 0.04% |
| April 1, 2025 | Schwendenman Andrew | Chief Accounting Officer | A | Employee Stock Option (right to buy) | 50000 | $0.00 | 50,000.0000 | 80,564,147 | 9999.99% | 0.06% |
| March 5, 2025 | BAKER BROS. ADVISORS LP | Not found | A | Non-Qualified Stock Option (right to buy)uy) | 64000 | $0.00 | 64,000.0000 | 83,498,892 | 9999.99% | 0.08% |
| March 5, 2025 | BAKER BROS. ADVISORS LP | Not found | A | Non-Qualified Stock Option (right to buy)uy) | 64000 | $0.00 | 64,000.0000 | 83,498,892 | 9999.99% | 0.08% |
| Dec. 16, 2024 | Patel Sushil | Chief Executive Officer | S | Common Stock | 10000 | $12.42 | 202,014.0000 | 78,570,135 | 4.72% | 0.01% |
| Nov. 18, 2024 | Sarchi Christopher | Chief Commercial Officer | S | Common Stock | 5207 | $10.78 | 87,045.0000 | 78,570,135 | 5.64% | 0.01% |
| Nov. 18, 2024 | Xynos Konstantinos | Chief Medical Officer | S | Common Stock | 7246 | $10.78 | 109,885.0000 | 78,570,135 | 6.19% | 0.01% |
| Sept. 4, 2024 | Balachandran Madhavan | Director | A | Employee Stock Option (right to buy) | 64000 | $0.00 | 64,000.0000 | 66,569,894 | 9999.99% | 0.10% |
| Aug. 30, 2024 | Astley-Sparke Philip | Executive Chairman | G | Common Stock | 50000 | $0.00 | 1,437,350.0000 | 66,569,894 | 3.36% | 0.08% |
| Aug. 16, 2024 | Hill Emily Luisa | Chief Financial Officer | S | Common Stock | 8938 | $10.18 | 101,057.0000 | 66,569,894 | 8.13% | 0.01% |
| June 7, 2024 | Xynos Konstantinos | Chief Medical Officer | S | Common Stock | 15881 | $7.50 | 117,131.0000 | 66,569,894 | 11.94% | 0.02% |
| May 16, 2024 | Astley-Sparke Philip | Executive Chairman | S | Common Stock | 37928 | $6.47 | 1,487,350.0000 | 66,569,894 | 2.49% | 0.06% |
| May 16, 2024 | Coffin Robert | Director | S | Common Stock | 11464 | $6.47 | 1,821,872.0000 | 66,569,894 | 0.63% | 0.02% |
| May 16, 2024 | Patel Sushil | Chief Executive Officer | S | Common Stock | 20194 | $6.47 | 212,014.0000 | 66,569,894 | 8.70% | 0.03% |
| May 16, 2024 | Xynos Konstantinos | Chief Medical Officer | S | Common Stock | 6367 | $6.47 | 133,012.0000 | 66,569,894 | 4.57% | 0.01% |
| May 16, 2024 | Love Colin | Chief Operating Officer | S | Common Stock | 17615 | $6.47 | 777,345.0000 | 66,569,894 | 2.22% | 0.03% |
| May 16, 2024 | Schwendenman Andrew | Chief Accounting Officer | S | Common Stock | 2298 | $6.47 | 38,238.0000 | 66,569,894 | 5.67% | 0.00% |
| May 16, 2024 | Sarchi Christopher | Chief Commercial Officer | S | Common Stock | 2218 | $6.47 | 92,252.0000 | 66,569,894 | 2.35% | 0.00% |
| April 1, 2024 | Weinand Dieter | Director | A | Stock Option (right to buy) | 32000 | $0.00 | 32,000.0000 | 66,569,894 | 9999.99% | 0.05% |
| April 1, 2024 | Oliger Christy J. | Director | A | Stock Option (right to buy) | 32000 | $0.00 | 32,000.0000 | 66,569,894 | 9999.99% | 0.05% |
| April 1, 2024 | Levitsky Hyam | Director | A | Stock Option (right to buy) | 32000 | $0.00 | 32,000.0000 | 66,569,894 | 9999.99% | 0.05% |
| April 1, 2024 | Schwendenman Andrew | Chief Accounting Officer | A | Common Stock | 17775 | $0.00 | 40,536.0000 | 66,569,894 | 78.09% | 0.03% |
| April 1, 2024 | Schwendenman Andrew | Chief Accounting Officer | A | Employee Stock Option (right to buy) | 53325 | $0.00 | 53,325.0000 | 66,569,894 | 9999.99% | 0.08% |
| April 1, 2024 | Patel Sushil | Chief Executive Officer | A | Employee Stock Option (right to buy) | 250000 | $0.00 | 250,000.0000 | 66,569,894 | 9999.99% | 0.38% |
| April 1, 2024 | Patel Sushil | Chief Executive Officer | A | Common Stock | 83335 | $0.00 | 232,208.0000 | 66,569,894 | 55.98% | 0.13% |
| April 1, 2024 | Peeples-Dyer Veleka | Director | A | Stock Option (right to buy) | 32000 | $0.00 | 32,000.0000 | 66,569,894 | 9999.99% | 0.05% |
| April 1, 2024 | Hill Emily Luisa | Chief Financial Officer | A | Employee Stock Option (right to buy) | 80000 | $0.00 | 80,000.0000 | 66,569,894 | 9999.99% | 0.12% |
| April 1, 2024 | Hill Emily Luisa | Chief Financial Officer | A | Common Stock | 26665 | $0.00 | 109,995.0000 | 66,569,894 | 32.00% | 0.04% |
| April 1, 2024 | Dhingra Kapil | Director | A | Stock Option (right to buy) | 32000 | $0.00 | 32,000.0000 | 66,569,894 | 9999.99% | 0.05% |
| April 1, 2024 | Xynos Konstantinos | Chief Medical Officer | A | Employee Stock Option (right to buy) | 80000 | $0.00 | 80,000.0000 | 66,569,894 | 9999.99% | 0.12% |
| April 1, 2024 | Xynos Konstantinos | Chief Medical Officer | A | Common Stock | 26665 | $0.00 | 139,379.0000 | 66,569,894 | 23.66% | 0.04% |
| April 1, 2024 | Pucci Paolo | Director | A | Stock Option (right to buy) | 32000 | $0.00 | 32,000.0000 | 66,569,894 | 9999.99% | 0.05% |
| April 1, 2024 | Sarchi Christopher | Chief Commercial Officer | A | Common Stock | 22225 | $0.00 | 94,470.0000 | 66,569,894 | 30.76% | 0.03% |
| April 1, 2024 | Sarchi Christopher | Chief Commercial Officer | A | Employee Stock Option (right to buy) | 66675 | $0.00 | 66,675.0000 | 66,569,894 | 9999.99% | 0.10% |
| April 1, 2024 | SLATTERY JOSEPH P | Director | A | Stock Option (right to buy) | 32000 | $0.00 | 32,000.0000 | 66,569,894 | 9999.99% | 0.05% |